Literature DB >> 19789570

Hepatitis: Monitoring drug therapy for hepatitis B--a global challenge?

Tin Nguyen1, Stephen Locarnini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19789570     DOI： 10.1038/nrgastro.2009.160

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  9 in total

1.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

Authors:  Chien-Jen Chen; Hwai-I Yang; Jun Su; Chin-Lan Jen; San-Lin You; Sheng-Nan Lu; Guan-Tarn Huang; Uchenna H Iloeje
Journal:  JAMA       Date:  2006-01-04       Impact factor: 56.272

Review 2.  EASL Clinical Practice Guidelines: management of chronic hepatitis B.

Authors: 
Journal:  J Hepatol       Date:  2008-10-29       Impact factor: 25.083

3.  Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.

Authors:  Stefan Zeuzem; Edward Gane; Yun-Fan Liaw; Seng G Lim; Adrian DiBisceglie; Maria Buti; Anuchit Chutaputti; Jens Rasenack; Jinlin Hou; Christopher O'Brien; Tuan T Nguyen; Jidong Jia; Thierry Poynard; Bruce Belanger; Weibin Bao; Nikolai V Naoumov
Journal:  J Hepatol       Date:  2009-02-12       Impact factor: 25.083

4.  Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.

Authors:  F Bonino; P Marcellin; G K K Lau; S Hadziyannis; R Jin; T Piratvisuth; G Germanidis; C Yurdaydin; M Diago; S Gurel; M-Y Lai; M R Brunetto; P Farci; M Popescu; P McCloud
Journal:  Gut       Date:  2006-11-24       Impact factor: 23.059

5.  Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.

Authors:  Uchenna H Iloeje; Hwai-I Yang; Jun Su; Chin-Lan Jen; San-Lin You; Chien-Jen Chen
Journal:  Gastroenterology       Date:  2006-03       Impact factor: 22.682

6.  Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.

Authors:  Daniel J Tenney; Ronald E Rose; Carl J Baldick; Kevin A Pokornowski; Betsy J Eggers; Jie Fang; Michael J Wichroski; Dong Xu; Joanna Yang; Richard B Wilber; Richard J Colonno
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

7.  Lamivudine for patients with chronic hepatitis B and advanced liver disease.

Authors:  Yun-Fan Liaw; Joseph J Y Sung; Wan Cheng Chow; Geoffrey Farrell; Cha-Ze Lee; Hon Yuen; Tawesak Tanwandee; Qi-Min Tao; Kelly Shue; Oliver N Keene; Jonathan S Dixon; D Fraser Gray; Jan Sabbat
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

8.  HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.

Authors:  Michael W Fried; Teerha Piratvisuth; George K K Lau; Patrick Marcellin; Wan-Cheng Chow; Graham Cooksley; Kang-Xian Luo; Seung Woon Paik; Yun-Fan Liaw; Peter Button; Matei Popescu
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

9.  Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

Authors:  Maurizia Rossana Brunetto; Francesco Moriconi; Ferruccio Bonino; George K K Lau; Patrizia Farci; Cihan Yurdaydin; Teerha Piratvisuth; Kangxian Luo; Yuming Wang; Stephanos Hadziyannis; Eva Wolf; Philip McCloud; Richard Batrla; Patrick Marcellin
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425
  9 in total
  5 in total

1.  Serum proteins in chronic hepatitis B patients treated with peginterferon alfa-2b.

Authors:  Sunida Kuakarn; Poorichaya SomParn; Pisit Tangkijvanich; Varocha Mahachai; Visith Thongboonkerd; Nattiya Hirankarn
Journal:  World J Gastroenterol       Date:  2013-08-21       Impact factor: 5.742

Review 2.  Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs.

Authors:  Fengmin Lu; Jie Wang; Xiangmei Chen; Dongping Xu; Ningshao Xia
Journal:  Front Med       Date:  2017-11-23       Impact factor: 4.592

3.  Serum HBV DNA plus RNA reflecting cccDNA level before and during NAs treatment in HBeAg positive CHB patients.

Authors:  Yang Wang; Yanna Liu; Hao Liao; Zhongping Deng; Dandan Bian; Yan Ren; Guangxin Yu; Yingying Jiang; Li Bai; Shuang Liu; Mei Liu; Li Zhou; Yu Chen; Xinyue Chen; Zhongping Duan; Fengmin Lu; Sujun Zheng
Journal:  Int J Med Sci       Date:  2022-05-09       Impact factor: 3.642

Review 4.  Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential.

Authors:  Maura Dandri; Joerg Petersen
Journal:  Clin Infect Dis       Date:  2016-06-01       Impact factor: 9.079

5.  Phase diagrams map the properties of antiviral agents directed against hepatitis B virus core assembly.

Authors:  Lichun Li; Srinivas Reddy Chirapu; M G Finn; Adam Zlotnick
Journal:  Antimicrob Agents Chemother       Date:  2012-12-03       Impact factor: 5.191
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.